NOT FOR INJECTION, CONSUMPTION, ADMINISTRATION, DIAGNOSTIC, OR THERAPEUTIC APPLICATION
Tirzepatide is a 39amino acid dual incretin receptor agonist that activates both GLP1 and GIP receptors, enhancing glucosedependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite [1] [2]
Nous nous engageons distribuer des mdicaments vtrinaires de haute qualit certifis BPF pour le march mondial depuis plus de 20 ans
Kidney problems (kidney failure): In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse
It is not approved by the FDA or any other regulatory body for human or veterinary use, and nothing in this guide constitutes guidance for human administration